Related Experiment Video

Updated: Jul 28, 2026

Prostaglandin Extraction and Analysis in Caenorhabditis elegans
08:50

Prostaglandin Extraction and Analysis in Caenorhabditis elegans

Published on: June 25, 2013

Oral antisecretory activity of prostaglandin E2 in man

S B Reele, D Bohan

    Digestive Diseases and Sciences
    |May 1, 1984
    PubMed

    More Related Videos

    Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents08:39

    Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents

    Published on: May 16, 2022

    Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea07:36

    Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

    Published on: December 23, 2022

    Related Concept Videos

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

    Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
    These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
    Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

    Pathophysiology of Peptic Ulcer Disease: Injurious Factors

    Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
    In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds to M3...
    Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

    Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

    Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining. Bicarbonate,...
    Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

    Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

    Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
    Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
    Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

    Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

    The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
    Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
    Peptic Ulcer Disease IV: Management01:26

    Peptic Ulcer Disease IV: Management

    Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
    The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
    Pharmacological management
    The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...